title: New insights into the mechanisms of the vasorelaxant effects of apocynin in rat thoracic aorta.
abstract: Apocynin is a naturally occurring acetophenone widely used as an inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Recent data suggested that apocynin might exert NADPH oxidase-independent pharmacological properties. Among them, vasorelaxant properties have been described, but the mechanisms still give rise to debates. The present study investigated the mechanisms involved in the vasorelaxant effect of apocynin on the in vitro model of rat isolated thoracic aortic rings. Apocynin (30 μM to 10 mM) induced a dose-dependent relaxation in both endothelium-intact and endothelium-denuded aortic rings with respective EC50 values of 0.78 ± 0.08 and 1.91 ± 0.21 mM. Endothelium removal or inhibition of nitric oxide (NO) synthase with N(ω)-nitro-L-arginine-methyl ester (L-NAME) significantly decreased but did not abolish the effect of apocynin. By contrast, apocynin-induced relaxation was unchanged after incubation with indomethacin or charybdotoxin plus apamin. In endothelium-denuded aortas, the vasorelaxant effect of apocynin was significantly reduced by glibenclamide but not by 4-aminopyridine nor by iberiotoxin. Apocynin significantly decreased Ca(2+)-induced contraction and inhibited intracellular Ca(2+) mobilization after contraction with phenylephrine. Finally, the acute intravenous injection of apocynin led to an immediate and transient hypotensive effect in spontaneously hypertensive rats (SHR). In conclusion, our data demonstrated that apocynin induces both endothelium-independent relaxant effects involving inhibition of Ca(2+) mobilization and activation of KATP channels in vascular smooth muscle cells and endothelium-dependent effects mediated by NO. These results should provide a basis for caution when interpreting results on the vascular effects of apocynin.
authors.affiliation: EA 3185 Fonctions et Dysfonctions Epithéliales, UFR des Sciences Médicales et Pharmaceutiques, 25030 Besançon, France.
authors.forename: François
authors.initials: F
authors.lastname: Senejoux
authors.forename: Corine
authors.initials: C
authors.lastname: Girard-Thernier
authors.forename: Alain
authors.initials: A
authors.lastname: Berthelot
authors.forename: Françoise
authors.initials: F
authors.lastname: Bévalot
authors.forename: Céline
authors.initials: C
authors.lastname: Demougeot
mesh_terms: D000098:Acetophenones / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology; D001013:Aorta, Thoracic / Q000187:drug effects* / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000378:metabolism; D006973:Hypertension / Q000188:drug therapy; D007275:Injections, Intravenous; D054086:KATP Channels / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D051381:Rats; D011918:Rats, Inbred SHR; D017208:Rats, Wistar; D014661:Vasoconstriction / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000098:Acetophenones; D000959:Antihypertensive Agents; D054086:KATP Channels; D014665:Vasodilator Agents; D009569:Nitric Oxide; C056165:acetovanillone; D002118:Calcium